(MedPage Today) — BERLIN — The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic colorectal cancer, a phase…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118047
Author :
Publish date : 2025-10-20 21:11:00
Copyright for syndicated content belongs to the linked Source.
